XML 47 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Revenues $ 2,965.1 $ 2,528.7
Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Regeneron's share of profits (losses) in connection with commercialization    
Disaggregation of Revenue [Line Items]    
Revenues 415.3 260.6
Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Sales-based milestone earned    
Disaggregation of Revenue [Line Items]    
Revenues 50.0 0.0
Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Reimbursement for manufacturing of commercial supplies    
Disaggregation of Revenue [Line Items]    
Revenues 160.8 105.6
Sanofi Collaboration Agreement, Antibody | Research and development expense | Reimbursement of research and development expenses    
Disaggregation of Revenue [Line Items]    
Revenues 36.5 30.1
Sanofi Collaboration Agreement, Antibody | Research and development expense | Regeneron's obligation for its share of Sanofi research and development expenses    
Disaggregation of Revenue [Line Items]    
Revenues (9.7) (11.9)
Sanofi Collaboration Agreement, Antibody | Selling, general and administrative expense | Reimbursement of commercialization-related expenses    
Disaggregation of Revenue [Line Items]    
Revenues 91.7 60.4
Sanofi Collaboration Agreement, Immuno-oncology | Collaboration revenue | Regeneron's share of profits (losses) in connection with commercialization | Outside United States    
Disaggregation of Revenue [Line Items]    
Revenues 2.8 (6.1)
Sanofi Collaboration Agreement, Immuno-oncology | Collaboration revenue | Reimbursement for manufacturing of ex-U.S. commercial supplies    
Disaggregation of Revenue [Line Items]    
Revenues 2.0 4.7
Sanofi Collaboration Agreement, Immuno-oncology | Research and development expense | Reimbursement of research and development expenses    
Disaggregation of Revenue [Line Items]    
Revenues 21.5 21.9
Sanofi Collaboration Agreement, Immuno-oncology | Selling, general and administrative expense | Reimbursement of commercialization-related expenses    
Disaggregation of Revenue [Line Items]    
Revenues 19.0 18.5
Sanofi Collaboration Agreement, Immuno-oncology | Selling, general and administrative expense | Regeneron's obligation for its share of Sanofi commercial expenses    
Disaggregation of Revenue [Line Items]    
Revenues (9.2) (7.7)
Sanofi Collaboration Agreement, Immuno-oncology | Cost of goods sold | Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits    
Disaggregation of Revenue [Line Items]    
Revenues (32.3) (30.4)
Sanofi Collaboration Agreement, Immuno-oncology | Other operating income | Amounts recognized in connection with up-front payments received    
Disaggregation of Revenue [Line Items]    
Revenues $ 18.1 $ 22.9